Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension

American Journal of Hypertension

Volumn 13, Issue 3, 2000, Pages 298-306

  Kohzuki, Masahiro ^a   Wu, Xue Min ^a   Kamimoto, Masahiro ^a   Yoshida, Kazunori ^a   Nagasaka, Makoto ^a   Kanazawa, Masayuki ^a   Yasujima, Minoru ^b   Saito, Takao ^c   Sato, Tokutaro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure; Cicletanine; Heart; Kidney; Proteinuria; SHR; WKY

Indexed keywords

ALBUMIN; CICLETANINE; DRUG VEHICLE; FREE RADICAL; GLUCOSE; NITROGEN; PROSTACYCLIN; PYRIDINE DERIVATIVE; STREPTOZOCIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY WEIGHT; CAPILLARY PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; ENDOTHELIUM INJURY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEART WEIGHT; HYPERTENSION; KIDNEY INJURY; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; UNINEPHRECTOMY; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ALBUMINURIA; ANALYSIS OF VARIANCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; BODY WEIGHT; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYPERTENSION; KIDNEY; KIDNEY GLOMERULUS; NECROSIS; PYRIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SYSTOLE; TIME FACTORS;

EID: 0034076098     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(99)00189-2     Document Type: Article

References (47)

1. Malherbe E., Auguet M., Delaflotte S., Priotzky E., Clostre F., Braquet P. Antihypertensive profile of cicletanine, a furopyridine derivative comparison with captopril, indapamide and prazocin . Pharmacol Res Commun. 20:1988;121-133.
2. Deby C., Bourgain R.H., Dupont G., Pincemail J., Garay R., Braquet P. Modulation of in vitro generation of prostanoids by drugs affecting membrane ion transport. Drugs Exp Clin Res. 14:1988;123-134.
3. Clostre F., Etienne A. General pharmacology of cicletanine. Drugs Exp Clin Res. 14:1988;73-82.
4. Quilley J., McGiff J.C. Arachidonic acid metabolism and urinary excretion of prostaglandins and thromboxane in rats with experimental diabetes mellitus. J Pharmacol Exp Ther. 234:1985;211-216.
5. Quilley J., McGiff J.C. Influence of insulin on urinary eicosanoid excretion in rats with experimental diabetes mellitus. J Pharmacol Exp Ther. 238:1986;606-611.
6. Zoja C., Perico N., Corna D., Benigni A., Gabanelli M., Morigi M., Bertani T., Remuzzi G. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. J Am Soc Nephrol. 1:1990;799-807.
7. Kohzuki M., Wu X.-M., Kamimoto M., Yoshida K., Watanabe M., Yasujima M., Sato T. Renal-protective effect of non-depressor dose of cicletanine in streptozotocin diabetic rats. J Hypertens. 17:1999;695-700.
8. Cooper M.E., Allen T.J., Macmillan P., Bach L., Jerums G., Doyle A.E. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am J Hypertens. 1:1988;1-5.
9. Emond C., Bompart G., Rakotoarivony J., Bascands J.L., Pecher C., Adam A., Tarrade T., Berthet P., Girolami J.P. Protective effect of cicletanine on hypertension-induced decreases in the renal kallikrein-kinin and prostaglandin systems in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 20:1992;601-607.
10. Szczepanska-Konkel M., Redlak M., Angielski S. Glibenclamid-sensitive K+ channels are responsible for angiotensin II hypersensitive contraction and atrial natriuretic factor refractoriness of glomeruli in low-sodium rats. Biochem Biophy Res Commun. 181:1991;871-876.
11. Alvares-Guerra M., Alda O., Morin E., Allard M., Garay R.P. Reduction by (-)-cicletanine of the vascular reactivity to angiotensin II in rats. J Cardiovasc Pharmacol. 28:1996;564-570.
12. Gerber J.G., Olson R.D., Nies A.S. Interrelationship between prostaglandins and renin release. Kidney Int. 19:1981;816-821.
13. Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Liu PF, Obara K, Saito T, Abe K: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 1995;13:97-103.
14. Yoshida K., Kohzuki M., Yasujima M., Kanazawa M., Abe K. Effects of benidipine, a calcium antagonist, on urinary kallikrein excretion and renal impairment in experimental diabetes. J Hypertens. 14:1996;215-222.
15. Kohzuki M., Yasujima M., Yoshida K., Kanazawa M., Yoshinaga K., Abe K. The kidney protecting effect of trandolapril in normotensive and hypertensive diabetic rats. Pharmacometrics. 44:1992;309-315.
16. Yoshida K., Yasujima M., Kohzuki M., Kanazawa M., Abe K. The effects of chronic treatment of calcium channel blockers and angiotensin converting enzyme inhibitors on renal function in the streptozotocin diabetic rats. Hypertens Res. 17:1994;35-41.
17. Kohzuki M, Kamimoto M, Wu X-M, Yoshida K, Yasujima M, Sato T: A model combining genetic hypertension with diabetes: diabetogenic effect of streptozotocin in spontaneously hypertensive rats (abstract). Proceedings of the 9th International Symposium on SHR and Cardiovascular Genetics, 1997, p 55.
18. Kohzuki M., Kanazawa M., Liu P.F., Yoshida K., Saito T., Yasujima M., Sato T., Abe K. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure the chronic effects on cardio- and reno-protection of angiotensin converting enzyme inhibitors . J Hypertens. 13:1995;1785-1790.
19. Saito T., Sumithran E., Glasgow E.F., Atkins R.C. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int. 32:1987;691-699.
20. Saito T, Sato H, Obara K, Yamakage K, Abe K, Furuyama T, Yoshinaga K: Progression of experimental focal glomerulosclerosis in the spontaneously hypertensive rat. J Lab Clin Med 1990;115:165-173.
21. Ikeda K., Nara Y., Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Anim. 25:1991;26-29.
22. Daniels B.S., Hostetter T.H. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes. 38:1989;981-986.
23. Hostetter T.H., Olson J.H., Rennke H.G., Venkatachalam M.A., Brenner B.M. Hyperfiltration in remnant nephrons a potentially adverse response to renal ablation . Am J Physiol. 241:1981;F85-F93.
24. Cohen M.P., Vasselli J.R., Neuman R.G., Witt J. Treatment with acarbose, an α-glucosidase inhibitor, reduces increased albumin excretion in streptozotocin-diabetic rats. Gen Pharmacol. 26:1995;1355-1361.
25. Brenner B.M. Nephron adaptation to renal injury or ablation. Am J Physiol. 249:1985;F324-F339.
26. Cohen M.P., Surma M.L., Wu V.Y. In vivo biosynthesis and turnover of glomerular basement membrane in diabetic rats. Am J Physiol. 242:1982;F385-F389.
27. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effects of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
28. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria. Lancet. 349:1997;1787-1792.
29. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:1996;587-593.
30. Uehara Y., Numabe A., Hirawa N., Kawabata Y., Iwai J., Ono H., Matsuoka H., Takabatake Y., Yagi S., Sugimoto T. Antihypertensive effects of cicletanine and renal protection in Dahl salt-sensitive rats. J Hypertens. 9:1991;719-728.
31. Zats R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 77:1986;1925-1930.
32. Johnston CI, Yasujima M, Clappison BH: The kallikrein-kinin system and angiotensin converting enzyme inhibition in hypertension, in Horovitz ZP (ed), Angiotensin Converting Enzyme Inhibitors - Mechanism of Action and Clinical Implications. Baltimore, Urban-Schwarzenberg, 1981123-139.
33. Jaffa A.A., Miller D.H., Bailex G.S., Chao J., Margolius H.S., Mayfield R.K. Abnormal regulation of renal kallikrein in experimental diabetes effects of insulin on prokallikrein synthesis and activation . J Clin Invest. 80:1987;1651-1659.
34. Mayfield RK, Margolius HS, Bailey GS, Miller DH, Seus DA, Squires J, Namn DH: Urinary and renal tissue kallikrein in the streptozotocin-diabetic rat. Diabetes 1985;34:22-28.
35. Kon V, Fogo A, Ichikawa I, et al: Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-550.
36. Damase-Michel C., Girolami J.P., Bascands J.L., Tran M.A., Moatti J.P., Pecher C., Berthet P., Tarrade T. Effects of cicletanine on vasoactive systems in conscious sinoaortic-denervated dogs. Fundam Clin Pharmacol. 5:1991;719-732.
37. Yasu T, Imanishi M, Kimura G, Tsuji T, Matsuoka H. Kuramochi M, Omae T: Short-term increase in prostaglandin I2 synthesis caused by cicletanine in patients with essential hypertension. Am J Hypertens 1995;8:944-948.
38. Anderson S, Brenner BM: The critical role of nephron mass and of intraglomerular pressure for initiation and progression of experimental hypertensive-renal disorders, in Laragh JH, Brenner BM (eds.): Hypertension; Pathophysiology, Diagnosis and Management. Raven Press, New York, 1990, pp 1163-1176.
39. Inscho E.W., Carmines P.K., Navar L.G. Prostaglandin influences on afferent arteriolar responses to vasoconstrictor agonists. Am J Physiol. 259:1990;F157-F163.
40. Deby C., Bourgain R.H., Andries R., Braquet P. Modulation of prostacyclin synthetase by cicletanine and drugs which affect ion transport. Pharmacol Res Commun. 20:1988;101-108.
41. Uehara Y., Kawabata Y., Hirawa N., Takada S., Nagata T., Numabe A., Iwai J., Sugimoto T. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats. Am J Hypertens. 6:1993;463-472.
42. Uehara Y., Numabe A., Kawabata Y., Nagata T., Iwai J., Matsuoka H., Yagi S., Takabatake Y., Sugimoto T. Evidence for medial-mass regression in the vascular wall of Dahl hypertensive rats by cicletanine treatment. J Cardiovasc Pharmacol. 18:1991;158-166.
43. Trimble E.R., Karakash C., Malaisse-Lagae F., Vassutine L., Renold A.E. Effects of intraportal islet transplantation on the transplanted tissue and the recipient pancreas. Functional studies. Diabetes. 29:1980;314-347.
44. ArRajab A., Ahren B. Long-term diabetologic effect of streptozotocin in rats. J Cardiovasc Pharmacol. 8:1993;50-57.
45. Seyer-Hansen K. Renal hypertrophy in experimental diabetes. Kidney Int. 23:1983;643-646.
46. Steffes M.W., Brown D.M., Mauer S.M. Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes. 27:1978;35-41.
47. O'Donnell M.P., Kasiske B.L., Daniels F.X., Keane W.F. Effect of nephron loss on glomerular hemodynamics and morphology in diabetic rats. Diabetes. 35:1986;1011-1015.